PATHWAY-2: spironolactone for resistant hypertension - Authors' reply.
UCL Institute of Cardiovascular Sciences, University College London and National Institute for Health Research, UCL/UCL Hospitals Biomedical Research Centre, London W1T 7DN, UK. Electronic address: bryan.williams@ucl.ac.uk.
Bryan
B
Williams
Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Dundee, UK.
Tom M
TM
MacDonald
Medicines Monitoring Unit, Medical Research Institute, University of Dundee, Dundee, UK.
Steven V
SV
Morant
The Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Morris J
MJ
Brown
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use*
D058668:Adrenergic alpha-1 Receptor Antagonists; D058671:Adrenergic beta-1 Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol